Cortechs.ai increases physician access to volumetric MRI Processing with additional scanner option.
(SAN DIEGO) Nov. 19, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that Toshiba Titan 3T MRI scanners are now supported by NeuroQuant®, the foremost medical device software for volumetric MRI processing. Cortechs.ai validated the Toshiba Titan 3T MRI scanners with MPower v3.5 to ensure accurate and consistent brain segmentation results.
This new capability provides hospitals, clinics, imaging and research centers worldwide with expanded MRI scanner options when looking to use NeuroQuant to automatically measure brain structures through 3D T1 MRI images. NeuroQuant, the first FDA cleared and CE marked software for measuring brain volumes and assessing brain atrophy, is used in the assessment of neurodegeneration, such as Alzheimer’s disease, epilepsy, multiple sclerosis, as well as, brain volume changes caused by brain trauma.
“We are excited to grow our MRI scanner options to include Toshiba Titan 3T MRI scanners, which is another step in our continuous improvement process to increase access to our capabilities,” said Guri Stark, Cortechs.ai’ CEO. “This expansion strengthens our goal of providing a vendor neutral product, allowing physicians and clinicians more freedom in MRI scanner choices when using NeuroQuant in their assessment of neurodegeneration.”
For more information about using NeuroQuant in Toshiba Titan 3T MRI scanners, please visit Cortechs.ai at Booth 1861 (Hall A, South) during Radiological Society of North America’s (RSNA) 2015 Annual Meeting (Nov. 29 – Dec. 4, McCormick Place, Chicago).
Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. Please visit cortechs.ai for further information.